NASDAQ:AXNX - Axonics Modulation Technologies Stock Price, Forecast & News

Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX."

Axonics Modulation Technologies Inc (NASDAQ:AXNX) posted its earnings results on Thursday, November, 14th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.14. The firm earned $1.31 million during the quarter, compared to the consensus estimate of $1.45 million. Axonics Modulation Technologies had a negative return on equity of 55.57% and a negative net margin of 1,530.43%. The business's revenue for the quarter was up 555.0% on a year-over-year basis. View Axonics Modulation Technologies' Earnings History.

Axonics Modulation Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Axonics Modulation Technologies.

Axonics Modulation Technologies issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10-10 million, compared to the consensus revenue estimate of $4.24 million.

8 brokerages have issued 12 month target prices for Axonics Modulation Technologies' shares. Their forecasts range from $38.00 to $48.00. On average, they anticipate Axonics Modulation Technologies' stock price to reach $43.13 in the next year. This suggests a possible upside of 36.9% from the stock's current price. View Analyst Price Targets for Axonics Modulation Technologies.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics Modulation Technologies in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axonics Modulation Technologies.

Press coverage about AXNX stock has been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Axonics Modulation Technologies earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Axonics Modulation Technologies.

Axonics Modulation Technologies saw a increase in short interest in December. As of December 31st, there was short interest totalling 5,340,000 shares, an increase of 11.9% from the December 15th total of 4,770,000 shares. Based on an average trading volume of 657,100 shares, the days-to-cover ratio is currently 8.1 days. Currently, 35.4% of the company's stock are short sold. View Axonics Modulation Technologies' Current Options Chain.

Some companies that are related to Axonics Modulation Technologies include Cantel Medical (CMD), Irhythm Technologies (IRTC), Glaukos (GKOS), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), Cardiovascular Systems (CSII), AtriCure (ATRC), Silk Road Medical (SILK), Atrion (ATRI), Shockwave Medical (SWAV), Tactile Systems Technology (TCMD), Cryolife (CRY), Luminex (LMNX), Orthofix Medical (OFIX) and Orthopediatrics (KIDS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics Modulation Technologies investors own include Oasis Petroleum (OAS), Alibaba Group (BABA), Home Depot (HD), Honeywell International (HON), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Cisco Systems (CSCO), CVS Health (CVS), Procter & Gamble (PG) and CSX (CSX).

(AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Axonics Modulation Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (2.14%) and Rhenman & Partners Asset Management AB (1.15%). Company insiders that own Axonics Modulation Technologies stock include Andera Partners, Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Danny L Dearen, Geoff Pardo, Healthcare Holding BV Gilde, John Woock, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen and Rinda Sama. View Institutional Ownership Trends for Axonics Modulation Technologies.

AXNX stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Rhenman & Partners Asset Management AB. Company insiders that have bought Axonics Modulation Technologies stock in the last two years include Bakker Juliet Tammenoms, Cormorant Asset Management, Lp, Healthcare Holding BV Gilde, Nancy Lynn Md Snyderman and Raymond W Cohen. View Insider Buying and Selling for Axonics Modulation Technologies.

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXNX stock can currently be purchased for approximately $31.50.

Axonics Modulation Technologies has a market capitalization of $900.90 million and generates $710,000.00 in revenue each year. The company earns $-32,480,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Axonics Modulation Technologies employs 87 workers across the globe.View Additional Information About Axonics Modulation Technologies.

The official website for Axonics Modulation Technologies is http://www.axonicsmodulation.com/.

Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322.